New weapon against tough head & neck cancers shows promise
NCT ID NCT05271604
Summary
This study tested an experimental drug called ozuriftamab vedotin for people with advanced head and neck cancer that had returned or spread. The main goals were to see if the drug could shrink tumors and how safe it was for patients. It included 42 adults whose cancer was not curable with surgery or radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Christiana Care Helen Graham Cancer Center
Newark, Delaware, 19713, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40202, United States
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Washington University Medical Siteman Cancer Center
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.